PATENT ASSETS. Owned Patents
PATENT ASSETS. The Seller has not received any written or oral notice or claim of infringement with respect to any of the Patent Assets and, to the Seller's knowledge, the Patent Assets do not infringe on the patent rights of a third party.
PATENT ASSETS. Assignor hereby irrevocably sells, transfers, conveys, assigns and delivers all of its right, title and interest of every kind and character throughout the world, including all reissues, continuations, divisonals in, to and under the Patent Assets (including, without limitation, the patents and patent applications set forth in Exhibit A hereto) to the full extent of its ownership or interest therein, including, without limitation, all rights and causes of action for infringement or misappropriation (past, present or future) of any Patent Asset, all rights to apply for or register any of the foregoing, and any and all other rights and interests arising out of, in connection with or in relation to the Patent Assets. At Closing, Seller shall execute and deliver to Patent Purchaser a confirmatory assignment covering each applicable Patent Asset for filing with the United States Patent and Trademark Office in the form attached hereto as Exhibit B (such form, the "Confirmatory Assignment").
PATENT ASSETS. Case Number: A01
PATENT ASSETS. =================================================================================================================================== Country Filed Serial # Issued Patent # Inventors =================================================================================================================================== [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]* [**] [**] [**] [**] *Application for restoration on file. [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]* [**] [**] [**] [**] [**] *The British Patent Office has allowed Atlantic's application for restoration, subject to payment of outstanding renewal fees, & recordation of the exclusive license and licensee's name change. These matters will be taken care of by the [**]. [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] **CONFIDENTIAL TREATMENT REQUESTED EXHIBIT 3.7 ----------- LIST OF AGREEMENTS ------------------ License Agreements
PATENT ASSETS. Compound Patent No. Country Filing Date Status ---------------------------------------------------------------------- [*] [*] PCT [*] [*] [*] Europe [*] [*] [*] USA [*] [*] [*] Canada [*] [*] [*] Japan [*] [*] [*] [*] Korea [*] [*] [*] Mexico [*] [*] [*] [*] Norway [*] [*] [*] [*] Chile [*] [*] [*] [*] Venezuela [*] [*] [*] [*] PCT [*] [*] [*] Europe [*] [*] [*] USA [*] [*] [*] Canada [*] [*] [*] Japan [*] [*] [*] [*] Korea [*] [*] [*] Mexico [*] [*] [*] Norway [*] [*] [*] [*] Brazil [*] [*] [*] Argentina [*] [*] [*] Chile [*] [*] [*] [*] Venezuela [*] [*] [*] [*] PCT [*] [*] [*] Argentina [*] [*] [*] Chile [*] [*] [*] Venezuela [*] [*] *Confidential Treatment Requested EXHIBIT 1.32 SPECIFICATIONS (Tentative synthesis route. Subject to adjustments and improvements by Uriach) [*] *Confidential Treatment Requested UR-12746 Sodium Salt- Tentative Specifications [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] Note: [*] *Confidential Treatment Requested SPECIFICATIONS OF PRODUCT FORMULATION [*] The stability of the following prototype is currently under study: [*][*] [*][*] [*][*] [*][*] [*] [*] All the excipients meet pharmacopoeial monographs and have been extensively used for oral products; tablets comply with the required quality standards. [*] [*] *Confidential Treatment Requested APPENDIX 3.7 CLINICAL TRIAL PRODUCT REQUIREMENTS -------------------------------------------------------------------------------- Appendix 3.7 -------------------------------------------------------------------------------- [*] [*] [*] -------------------------------------------------------------------------------- [*] [*] -------------------------------------------------------------------------------- [*] [*] [*] -------------------------------------------------------------------------------- [*] [*] [*] -------------------------------------------------------------------------------- [*] [*] -------------------------------------------------------------------------------- [*] [*] -------------------------------------------------------------------------------- [*] [*] [*] -------------------------------------------------------------------------------- [*] [*] [*] -------------------------------------------------------------------------------- [*] [*] -------------------------------------------------------------------------------- [*] [*] [*] -----------------------------------------------------------------------------...
PATENT ASSETS. Any and all Patent Assets of Netscape and/or AOL (the “Excluded Patents”), it being understood that Buyer shall not purchase or acquire any Patent Assets of Netscape or AOL or any license, right or interest in, to or under such Patent Assets except for the express license granted pursuant to the Patent License.
PATENT ASSETS. DOCKET SUMMARY OF CLAIMS CURRENT STATUS (US FILING) --------------------------------------------------------------------------------------------------------------------- PRO93-13 Use of aldehyde/aromatic sulfonic acid condensates to Abandoned in favor of (11/23/93) inhibit gp120/CD4 binding and HIV infection of CD4+ PRO93-13A cells in an individual and in blood preparations. --------------------------------------------------------------------------------------------------------------------- PRO93-13A Use of aldehyde/aromatic sulfonic acid condensates to Issued as U. S. Patent 5,614,559 (5/19/94) inhibit or treat HIV infection in an individual, and to (3/25/97) inhibit HIV infection in a blood preparation. Filed in PCT (11/17/94) EPO Application contains composition claims. National/regional filings in Canada, Japan, EPO (only) (5/23/96) --------------------------------------------------------------------------------------------------------------------- PRO93-13A2** Use of aldehyde/aromatic sulfonic acid condensates to Issued as U. S. Patent 5,677,343 (6/6/95) prevent or treat HIV infection in an individual, and to (10/14/97) inhibit HIV infection in a blood preparation. No international filing Composition claims abandoned. --------------------------------------------------------------------------------------------------------------------- PRO93-13AB** Composition claims to narrow or monodispersed Issued as U. S. Patent 6,075,050 (6/6/95) condensation polymer of naphthalene sulfonic acid and (6/13/00) aldehyde. Method claims abandoned. No international filing --------------------------------------------------------------------------------------------------------------------- [*] [*] [*] --------------------------------------------------------------------------------------------------------------------- PRO97-01 Method of preventing pregnancy. Issued as U.S. Patent 5,958,399 (5/1/97) (9/28/99) Filed in PCT and South Africa (4/30/98); Allowed in South Africa (2/25/99) National/regional filings in EPO, Russian Fed., Canada, Mexico, Brazil, China, Japan, S. Korea, Australia and New Zealand --------------------------------------------------------------------------------------------------------------------- ----------------------- * Confidential treatment requested. ** PRO93-13A2, AB, and AC filed as identical applications; AC abandoned SCHEDULE 3.7 THIRD PARTY AGREEMENTS
PATENT ASSETS. Subject to the terms and conditions of this Agreement, effective at Closing, Seller hereby sells, transfers, conveys, assigns and delivers all of Seller's right, title and interest in, to and under the Patent Assets (as defined below) to Patent Purchaser and, effective at Closing and subject to the terms and conditions hereof, Patent Purchaser hereby purchases all such right, title and interest in, to and under the Patent Assets. "Patent Assets" means all Patents of Seller related to the Business, including as conducted at or prior to Closing, as Proposed to be Conducted by Seller or as set forth on Schedule 1.2. Seller and Patent Purchaser shall at Closing enter into a Patent Assignment Agreement substantially in the form attached hereto as Exhibit B (the "Patent Assignment Agreement").
PATENT ASSETS
